ASG 5ME is a powerful, specific connection that, says Daniel von Hoff, a researcher, the most important phase I study clínico. cancer pancreas is designed to selectively kill cancer cells, rapid growth and is difficult to treat cancer to form the fourth leading cause of death from cancer in the United States.
"" Agreement on guarantees 5ME is aimed at who have currently no good prognosis with therapies disponibles.estamos very happy about this exciting agent in a clinical trial for patients with offer advanced pancreatic cancer, pancreatic cancer, "Says Dr. von Hoff."Our goal at the Virginia g."Piper Cancer Center is to provide medicine assassination cell best individually possible targeted treatments and agreement on guarantees 5ME fits the Bill."
An antibody against a target uses the new complex research pancreático.El monoclonal antibody monoklonale located in more than 90 percent of cancer patients a high-performance molecule offers Dipropylenglykolmonomethylether glycol Dipropylenglykolmonomethylether Auristatin E (MMAE) called selective kills pancreatic cancer cells.
It is a precision, which is designed to prevent that cells, specifically not to increase anti tumor activity in preclinical models and potentially reduce toxic effects of conventional chemotherapy approach, says Dr. from Hoff.Los researchers study to assess the drug, to identify security and compatibility and the maximum tolerated dose.
Virginia g. Piper was at Scottsdale Healthcare Cancer Center the first patients access to agreement guarantees 5ME.The researchers expect to register up to 50 patients in clinical trials of the drug in several centers in the United States.
The drug was developed by Seattle genetics, Inc. of Bothell, Washington and Agensys, Inc., a subsidiary of basis Tokyo Astellas Pharma Inc..
More than 36,000 people expected that the dying from pancreatic cancer in 2010, according to the American society. known cancer patients with pancreatic cancer dies advanced a year of diagnosis.
The 2001 opened Centre cancer Virginia g. Piper at Scottsdale healthcare as the first principal in greater Phoenix provide comprehensive cancer diagnosis, treatment, prevention and support services in a single Standort.La Commission on American College of surgeons cancer research Cancer Center has awarded accreditation with congratulations for the Scottsdale Healthcare Cancer program.
Dr. von Hoff is Chief Science in Virginia g. Piper at Scottsdale Healthcare Cancer Center and medical Chief at the Translational Genomics Research Institute (TGen).
Research in the middle of the cancer Virginia g. Piper at Scottsdale healthcare is carried out in cooperation with TGen and Scottsdale Healthcare - Research - Institute allows that molecular and genomic discoveries to reach patients bedside therapies on concrete objectives quickly in clinical trials in the patient's tumor aligned.
Read More Popular News at OneNewz.com
0 comments:
Post a Comment